Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Autolus Therapeutics: A Strong Buy on Promising Obe-cel Developments and Strategic Readiness
Q1 2024 Autolus Therapeutics PLC Earnings Call
Q1 2024 Autolus Therapeutics PLC Earnings Call Transcript
Crude Oil Gains 1%; GameStop Shares Plunge
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)
Autolus Therapeutics GAAP EPS of -$0.24 misses by $0.09, revenue of $10.09M misses by $14.96M
Options Volatility and Implied Earnings Moves Today, May 17, 2024
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
Autolus Therapeutics Q1 2024 Earnings Preview
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.